Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
Novel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatm...
Saved in:
Main Authors: | Shigeki Ito, Tatsuo Oyake, Kazunori Murai, Yoji Ishida |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2013/651902 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01) -
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020-01-01) -
Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01) -
Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide
by: Iuliana Vaxman, et al.
Published: (2020-01-01) -
Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
by: Vania dos Santos Nunes-Nogueira, et al.
Published: (2022-06-01)